Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer

Jean-Pascal Machiels, MD
Published: Monday, Jun 19, 2017



Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.
 


Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

The main adverse event to expect when treating a patient with pembrolizumab for head and neck cancer are endocrine side effects. However, it is also important to be aware of possible serious adverse events such as colitis or liver toxicities, states Machiels.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Publication Bottom Border
Border Publication
x